A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis

Andrea Francis, Antonio Jimenez, Swaminathan Sundaresan, Brent Kelly

JAAD Case Reports · 2020 · 26 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

Enfortumab vedotin is a novel treatment for metastatic urothelial carcinoma. In 2019, the United States Food and Drug Administration approved the drug as a third-line treatment for patients who had failed in previous trials of programmed cell death protein 1 and platinum-based chemotherapeutic agents.1 The drug has demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile.2 The adverse effects of enfortumab vedotin include fatigue, peripheral neuropathy, alopecia, and rash.

References

4